Published in J Pharm Pharmacol on October 01, 1999
Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech (2007) 1.05
Characterization and In Vitro Skin Permeation of Meloxicam-Loaded Liposomes versus Transfersomes. J Drug Deliv (2010) 1.01
Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J (2009) 0.93
Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J (2012) 0.88
Evaluation of meloxicam-loaded cationic transfersomes as transdermal drug delivery carriers. AAPS PharmSciTech (2012) 0.84
Lipid Vesicles for the Skin Delivery of Diclofenac: Cerosomes vs. Other Lipid Suspensions. Adv Pharm Bull (2015) 0.80
Transdermal delivery of an anti-cancer drug via w/o emulsions based on alkyl polyglycosides and lecithin: design, characterization, and in vivo evaluation of the possible irritation potential in rats. AAPS PharmSciTech (2010) 0.78
Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J (2014) 0.77
Investigation of the mechanism of enhanced skin penetration by ultradeformable liposomes. Int J Nanomedicine (2014) 0.76
Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med (2015) 0.76
Improved skin permeation of methotrexate via nanosized ultradeformable liposomes. Int J Nanomedicine (2016) 0.76
Influence of the flexible liposomes on the skin deposition of a hydrophilic model drug, carboxyfluorescein: dependency on their composition. ScientificWorldJournal (2012) 0.75
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Problems in assessing contents of metered dose inhalers. BMJ (1993) 3.07
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
Starch-Ampicillin Agar for the Quantitative Detection of Aeromonas hydrophila. Appl Environ Microbiol (1985) 1.72
Minimum standards for the management of cleft lip and palate: efforts to close the audit loop. Royal College of Surgeons of England. Ann R Coll Surg Engl (1996) 1.72
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett (1990) 1.47
Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharm Res (1991) 1.46
Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci (1999) 1.45
Influence of surgeon's experience on speech outcome in cleft lip and palate. Lancet (1999) 1.44
Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci (2008) 1.43
Migraine after bone-marrow transplantation. Lancet (1989) 1.43
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
The incidence of impacted teeth. A survey at Harlem hospital. Oral Surg Oral Med Oral Pathol (1970) 1.35
Submandibular duct sialolith of unusual size and shape. J Oral Surg (1975) 1.31
Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev (2003) 1.30
Effects of freezing on human skin permeability. J Pharm Pharmacol (1984) 1.27
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology (1999) 1.25
Sexual difficulties of chronic pain patients. Clin J Pain (2001) 1.25
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. Cleft Palate Craniofac J (2001) 1.21
Systematic review of outpatient services for chronic pain control. Health Technol Assess (1997) 1.19
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (1985) 1.17
Xenobiotic metabolism in motor neuron disease. Lancet (1988) 1.16
Xenobiotic metabolism in Parkinson's disease. Neurology (1989) 1.16
Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm (2000) 1.15
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. Cleft Palate Craniofac J (2001) 1.12
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol (1990) 1.10
The development of a battery of measures for assessing physical functioning of chronic pain patients. Pain (1994) 1.08
Spinal cord stimulation and the relief of chronic pain. J Neurol Neurosurg Psychiatry (1987) 1.06
Sesquiterpene components of volatile oils as skin penetration enhancers for the hydrophilic permeant 5-fluorouracil. J Pharm Pharmacol (1994) 1.05
The 'Iceman': molecular structure of 5200-year-old skin characterised by Raman spectroscopy and electron microscopy. Biochim Biophys Acta (1995) 1.03
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 1: background and methodology. Cleft Palate Craniofac J (2001) 1.03
Extrapyramidal reactions to anti-inflammatory drugs. J Neurol Neurosurg Psychiatry (1988) 1.02
Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst (1992) 1.02
Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science (1979) 1.01
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer (1970) 1.01
Smoking habits of Florida physicians revisited. JFMA (1972) 1.01
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut (2005) 1.00
Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 1.00
Patients' and professionals' understandings of the causes of chronic pain: blame, responsibility and identity protection. Soc Sci Med (1997) 0.99
Motoneurone disease as manifestation of pesticide toxicity. Lancet (1987) 0.99
Action of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. I. Infinite dose technique. J Invest Dermatol (1988) 0.99
Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet (1996) 0.98
Derepression of synthesis of the aminoacyl-transfer ribonucleic acid synthetases for the branched-chain amino acids of Escherichia coli. J Bacteriol (1974) 0.98
Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J Pharm Pharmacol (2001) 0.98
Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology (1990) 0.98
Bax inhibitor 1 in apoptosis and disease. Oncogene (2011) 0.97
Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer (1994) 0.97
Are the Peer Assessment Rating Index and the Index of Treatment Complexity, Outcome, and Need suitable measures for orthognathic outcomes? Eur J Orthod (2006) 0.96
Characterization of the Aeromonas hydrophila group isolated from retail foods of animal origin. J Clin Microbiol (1989) 0.95
Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells (review). Anticancer Res (1990) 0.95
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene (2010) 0.95
S-methylation in motorneuron disease and Parkinson's disease. Lancet (1989) 0.94
Plagiarism, retraction and the future. Hum Reprod (2011) 0.94
Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis (2005) 0.94
Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis (2003) 0.94
Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. J Pharm Pharmacol (1995) 0.93
Wide-angle X-ray diffraction of human stratum corneum: effects of hydration and terpene enhancer treatment. J Pharm Pharmacol (1994) 0.93
Bioavailability of topical steroids. Dermatologica (1976) 0.93
Hyponatraemia as a cause of reversible ataxia. Br Med J (Clin Res Ed) (1986) 0.92
Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci (1996) 0.92
Vasoconstrictor activities of some novel synthetic steroids in alcoholic solution. J Invest Dermatol (1975) 0.92
Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol (1989) 0.92
Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain (1994) 0.92
Toxicity of sulphur-containing compounds to neuronal cell lines. J Neurol Sci (1995) 0.91
Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer (1996) 0.91
Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry (2003) 0.91
Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet (1987) 0.90
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med (1998) 0.90
Prospects in NSAID-derived chemoprevention of colorectal cancer. Biochem Soc Trans (2005) 0.90
Skin hydration and possible shunt route penetration in controlled estradiol delivery from ultradeformable and standard liposomes. J Pharm Pharmacol (2001) 0.90
Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans (2005) 0.89
Bonding of metal attachments to teeth for treatment of mandibular fractures. J Oral Surg (1974) 0.89
Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications. Br J Dermatol (1977) 0.89
IGFBP-3 and apoptosis--a license to kill? Apoptosis (2001) 0.88
An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol (1995) 0.88
Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm (2004) 0.88
Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol (1974) 0.88
The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis (2012) 0.87
Effect of penetration enhancers on the permeation of mannitol, hydrocortisone and progesterone through human skin. J Pharm Pharmacol (1987) 0.87
The neuropathy of the critically ill. Br Med J (Clin Res Ed) (1986) 0.87
Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int J Pharm (2000) 0.87
In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology (1998) 0.87
The chewing stick: its uses and relationship to oral health. J Prev Dent (1978) 0.86
Panfacial cellulitis with contralateral orbital cellulitis and blindness after tooth extraction. J Oral Surg (1977) 0.86
Validation of the WHOQOL-100: pain management improves quality of life for chronic pain patients. Clin J Pain (2001) 0.86
Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions. Int J Pharm (2010) 0.86
Acute epidural abscess. Am J Emerg Med (1987) 0.86
Self-attempted endodontics--a case report. ASDC J Dent Child (1969) 0.86